研究单位：[1]Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China, 510060[2]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China,510060[3]Peking University Third Hospital,Beijing,China[4]Sichuan Cancer Hospital,Chengdu,China[5]Fujian Province Cancer Hospital,Fuzhou,China[6]Guizhou Cancer Hospital,Guiyang,China[7]Zhejiang Cancer Hospital,Hangzhou,China[8]Jiangxi Cancer Hospital,Nanchang,China[9]The First Affiliated Hospital of Guangxi Medical University,Nanning,China[10]Fudan University Shanghai Cancer Center,Shanghai,China[11]Zhongnan Hospital of Wuhan University,Wuhan,China[12]Xijing Hospital,Xi'an,China[13]The First Affiliated Hospital of Xiamen University,Xiamen,China
This is a multicenter, open-label, randomized, controlled, phase III trial. The purpose of this trial is to evaluate the efficacy and toxicity of anti-PD-1 antibody combined with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.
